Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Bull Exp Biol Med ; 161(4): 538-41, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27591876

RESUMEN

Biocompatibility of a new tracheal matrix is studied. The new matrix is based on polymeric ultra-fiber material colonized by mesenchymal multipotent stromal cells. The experiments demonstrate cytoconductivity of the synthetic matrices and no signs of their degradation within 2 months after their implantation to recipient mice. These data suggest further studies of the synthetic tracheal matrices on large laboratory animals.


Asunto(s)
Células Madre Mesenquimatosas/citología , Ingeniería de Tejidos/métodos , Andamios del Tejido/efectos adversos , Andamios del Tejido/química , Tráquea/citología , Animales , Células Cultivadas , Masculino , Células Madre Mesenquimatosas/fisiología , Ratones , Ratones Endogámicos C57BL
2.
Bull Exp Biol Med ; 153(1): 21-4, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22808484

RESUMEN

Activity of plasma proteolytic systems (fibrin formation, fibrinolysis, and anticoagulant system) and the possibility for correction of changes in these systems with erythropoietin were studied in experiments on outbred albino rats with experimental renal failure. Renal failure was induced by a single subcutaneous injection of mercury chloride (II). The parameters were estimated on day 5 postinjection. Erythropoietin in a single dose of 5000 U/kg was administered on day 4. Renal failure was accompanied by activation of fibrin formation (with factors of the common and intrinsic pathways of blood coagulation), increase in antithrombin activity, and inhibition of the fibrinolytic system. Treatment with erythropoietin led to partial recovery of fibrin formation and fibrinolysis. Under analytical in vitro conditions, 30-min incubation of whole blood from healthy donors with erythropoietin in doses of 1.9-30.0 U/liter was followed by a dose-dependent inhibition of the fibrin formation system and activation of fibrinolysis.


Asunto(s)
Coagulación Sanguínea/efectos de los fármacos , Eritropoyetina/farmacología , Eritropoyetina/uso terapéutico , Fibrinólisis/efectos de los fármacos , Insuficiencia Renal/tratamiento farmacológico , Animales , Fibrina/metabolismo , Humanos , Masculino , Distribución Aleatoria , Ratas , Insuficiencia Renal/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA